All articles tagged with #hereditary angioedema
Intellia Therapeutics’ Phase 3 study of lonvo-z, its in vivo CRISPR-based treatment for hereditary angioedema, showed an 87% reduction in attack rates versus placebo after a single dose, with over 60% of patients attack-free, prompting an FDA rolling submission and positioning lonvo-z as the second approved CRISPR medicine and the first in vivo gene-editing therapy.
Intellia Therapeutics reported positive topline Phase 3 HAELO results for lonvo-z (NTLA-2002), a one-time in vivo CRISPR therapy for hereditary angioedema that achieved its primary endpoint with an 87% reduction in attacks over six months, 62% attack- and therapy-free, and favorable safety; the company has initiated a rolling FDA Biologics License Application with a potential U.S. launch in the first half of 2027, marking a global first for in vivo gene editing.
Intellia Therapeutics said its one-time, in vivo CRISPR-based treatment for hereditary angioedema met its Phase 3 primary endpoint, reducing attacks by 87% vs placebo and achieving 62% attack-free patients at six months after a liver-directed infusion, with a favorable safety profile. The company has started a rolling FDA submission and targets a U.S. launch in 2027 if approved.
Crispr and Intellia stocks surged following promising updates on their gene-editing therapies, with Crispr showing potential for a one-time cholesterol treatment and Intellia demonstrating a near-cure for hereditary angioedema, leading to significant stock gains despite recent setbacks in the sector.
A single-dose gene therapy using CRISPR has shown promising results in treating hereditary angioedema, a rare genetic disorder causing painful and potentially fatal swelling. Patients in a human trial reported dramatic improvements in their health and quality of life, with some describing it as a "medical magic wand." The treatment corrects the C1 kallikrein gene and has the potential to transform the lives of those affected by the condition, although it comes with a high cost.
A groundbreaking gene therapy has shown promising results in treating hereditary angioedema, a rare disorder causing painful and potentially fatal swelling. Patients in the trial experienced dramatic improvements, with some being able to come off long-term medication and return to normal life. The therapy, using Crispr gene editing, aims to provide a permanent cure by targeting the genetic mutation causing the condition. While larger trials are ongoing, the high cost of one-shot gene therapies may limit accessibility, but the results offer hope for a potential cure for some sufferers.
The FDA has approved Intellia Therapeutics to begin testing a drug that uses CRISPR gene editing in vivo, marking the first time ever that the FDA has approved such testing. The drug would prevent swelling attacks in people with a genetic condition called hereditary angioedema. Typically, treatments and drugs that utilize CRISPR take place outside the body, but Intellia's edited media finds its own way to the liver rather than being injected there.